Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. (Q44534981)
Jump to navigation
Jump to search
scientific article published on 5 September 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. |
scientific article published on 5 September 2012 |
Statements
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis (English)
Sonya J Snedecor
Satyin Kaura
Marc F Botteman
5 September 2012